Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist

Kimihiro Okubo, Professor, Department of Otolaryngology, Nippon Medical School Pollen allergy approval for Novartis’ asthma drug Xolair (omalizumab) last year caused quite a stir over its potential impact on health finances in Japan, but a specialist says its actual use...read more